Clinical Trials

420 enrolled

Hematologic Neoplasms

NCT04771572 2026-05-05

Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.

LymphoidMyeloidOther hematologic neoplasmPlasma cell

100 enrolled

Lymphoma, Non-Hodgkin, Multiple Myeloma, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic, T-Cell, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Primary Myelofibrosis

NCT04996875 2026-05-05

APEX

LymphoidMyeloidOther hematologic neoplasm

140 enrolled

Hematologic Diseases, Hypersensitivity, Immune Complex Diseases, Immune System Diseases, Leukemia, Leukemia, Mast-Cell, Leukemia, Myeloid, Mastocytosis, Myeloproliferative Disorders, Neoplasms, Neoplasms by Site, Neoplasms, Connective Tissue, Skin Diseases, Soft Tissue Neoplasms, Urticaria Pigmentosa, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Mastocytosis, Systemic

NCT07195916 2026-05-04

A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies

DermatologicGenitourinaryLymphoidOther hematologic neoplasm

280 enrolled

Carcinoma, Renal Cell, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Hematologic Neoplasms

NCT04588922 2026-05-01

Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML

160 enrolled

Lymphoma, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute, Hematologic Neoplasms

NCT05347225 2026-04-30

MK-1026-005

12 enrolled

Hematologic Neoplasms

NCT04844866 2026-04-29

DALY 2-EU

213 enrolled

MyeloidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse, Hematologic Neoplasms

NCT05593185 2026-04-24

Expanded Access Program (EAP) for Galinpepimut-S (GPS) in Patients Diagnosed With AML or MDS

Available

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Hematologic Neoplasms

NCT06665100 2026-04-24

PUL-042 Treatment in Patients With Parainfluenza Virus (PIV), Human Metapneumovirus (hMPV) or Respiratory Syncytial Virus (RSV)

100 enrolled

Hematologic Neoplasms

NCT06782373 2026-04-24

A Study to Assess the Effectiveness and Safety of Pacritinib in Patients With VEXAS Syndrome (PAXIS)

MyeloidOther hematologic neoplasm

78 enrolled

VEXAS syndrome, Myelodysplastic Syndromes, Hematologic Neoplasms

NCT03145181 2026-04-23

MajesTEC-1

302 enrolled 1 FDA

Hematologic Neoplasms

NCT05428969 2026-04-23

BEXMAB

MyeloidOther hematologic neoplasm

181 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms

NCT03837899 2026-04-21

Durvalumab and Tremelimumab for Pediatric Malignancies

50 enrolled 59 charts

Neoplasms, Hematologic Neoplasms

NCT03328078 2026-04-16

CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)

152 enrolled

Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Neoplasms, Recurrence, Hematologic Neoplasms

NCT07504458 2026-04-16

QUATRO-APL

Phase 3 Recruiting

150 enrolled

Hematologic Diseases, Leukemia, Neoplasms, Leukemia, Promyelocytic, Acute, Hematologic Neoplasms

NCT06823167 2026-04-15

A Phase 1 Study of IM-1021 in Participants With Advanced Cancer

117 enrolled

Hematologic Neoplasms

NCT07216443 2026-04-15

Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

MyeloidOther hematologic neoplasmOther neoplasm

80 enrolled

Acute Disease, Bone Marrow Diseases, Disease, Graft vs Host Disease, Hematologic Diseases, Immune System Diseases, Immunoproliferative Disorders, Leukemia, Myelodysplastic Syndromes, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Pathologic Processes, Precancerous Conditions, Preleukemia, Syndrome, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Disease Attributes

NCT06001788 2026-04-14

Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

171 enrolled

Phase 2 Active not recruiting

Leukemia, Leukemia, Myeloid, Neoplasms by Histologic Type, Leukemia, Myeloid, Acute, Hematologic Neoplasms

NCT04557098 2026-04-13

MajesTEC-1

194 enrolled 1 FDA

Hematologic Neoplasms

NCT04696809 2026-04-13

A Study of Teclistamab in Japanese Participants With Relapsed or Refractory Multiple Myeloma

40 enrolled

Hematologic Neoplasms

NCT07523555 2026-04-13

ADAPT-HEM

LymphoidMyeloidOther hematologic neoplasmPlasma cell

96 enrolled

Blastic Plasmacytoid Dendritic Cell Neoplasm, Burkitt Lymphoma, Leukemia, Plasma Cell, Multiple Myeloma, Recurrence, Leukemia, Myeloid, Acute, Lymphoma, B-Cell, Lymphoma, T-Cell, Peripheral, Hematologic Neoplasms, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT04684108 2026-04-07

SG301 Safety Study in Subjects With Relapsed or Refractory Multiple Myeloma and Other Hematological Malignancies

Other hematologic neoplasmPlasma cell

61 enrolled

Multiple Myeloma, Recurrence, Hematologic Neoplasms

NCT02494258 2026-04-02

A Study to Evaluate Long-term Safety of CC-486 (Oral Azacitidine) in Subjects With Hematological Disorders

Phase 2 Completed

5 enrolled 10 charts

Hematologic Diseases, Neoplasms, Hematologic Neoplasms

NCT05753501 2026-03-27

Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies

135 enrolled

Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone, Hematologic Neoplasms, Lymphoma, Mantle-Cell

NCT06645886 2026-03-25

A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Hematologic Malignancies

13 enrolled

Phase 1 Not yet recruiting

Hematologic Neoplasms

NCT07485504 2026-03-20

Safety and Efficacy of DIT101 in Relapsed or Refractory Hematologic Malignancies

15 enrolled

Recurrence, Hematologic Neoplasms

NCT03838926 2026-03-16

Tolerability Study of Trichostatin A In Subjects With Relapsed or Refractory Hematologic Malignancies

42 enrolled

GenitourinaryLymphoidOther hematologic neoplasm

Neoplasms, Recurrence, Hematologic Neoplasms

NCT07474051 2026-03-16

PERSIST

Enrolling by invitation

178 enrolled

Prostatic Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute, Lymphoma, B-Cell, Hematologic Neoplasms

NCT05735184 2026-03-13

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

Other hematologic neoplasmSarcoma

420 enrolled

Leukemia, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Sarcoma, Myeloid

NCT05332054 2026-03-12

LTFS

Enrolling by invitation

150 enrolled

LymphoidOther hematologic neoplasmPlasma cell

Lymphoma, Lymphoma, Non-Hodgkin, Multiple Myeloma, Leukemia, Myeloid, Acute, Lymphoma, B-Cell, Hematologic Neoplasms

NCT07154823 2026-03-03

Aquarius

Recruiting

550 enrolled

125 enrolled 18 charts 1 FDA

Lymphoma, Follicular, Leukemia, Myeloid, Acute, Hematologic Neoplasms

NCT02730299 2026-02-25

Stem Cell Transplantation With NiCord® (Omidubicel) vs Standard UCB in Patients With Leukemia, Lymphoma, and MDS

Phase 3 Completed

LymphoidMyeloidOther hematologic neoplasm

Lymphoma, Myelodysplastic Syndromes, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07424833 2026-02-20

A Study of APG-3288 in Relapsed/Refractory Blood Cancers

Phase 1 Not yet recruiting

180 enrolled

Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Recurrence, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Hematologic Neoplasms, Lymphoma, Mantle-Cell

NCT05005442 2026-02-19

A Study of Pembrolizumab/Vibostolimab (MK-7684A) in Relapsed/Refractory Hematological Malignancies (MK-7684A-004, KEYVIBE-004)

Phase 2 Completed

192 enrolled 22 charts

Hematologic Neoplasms

NCT07036133 2026-02-11

SPI-FOL-102

24 enrolled

Hematologic Neoplasms

NCT06652633 2026-02-05

Hesperia

Phase 3 Recruiting

546 enrolled

Hematologic Neoplasms

NCT06756451 2026-01-30

This Study is a FIH Study Which is Required to Understand the PK Characteristics, MTD, RP2D and Safety Profile.

71 enrolled

Neoplasms, Hematologic Neoplasms

NCT06179511 2026-01-29

Study of AZD9829 in CD123+ Hematological Malignancies

56 enrolled

Hematologic Neoplasms

NCT04243499 2026-01-27

EVICTION

292 enrolled

LymphoidMyeloidOther hematologic neoplasm

Hematologic Neoplasms

NCT05665530 2026-01-26

A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies

Phase 1 Completed

86 enrolled

Myelodysplastic Syndromes, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Lymphoma, T-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Hematologic Neoplasms, Lymphoma, Mantle-Cell

NCT06359002 2026-01-20

Safety, Pharmacokinetics, and Preliminary Efficacy of BYON4413 in Acute Myeloid Leukemia and Myelodysplastic Neoplasms.

16 enrolled